Who Recovers? Massive Review Reveals What Predicts Remission Before Psychosis Strikes

Every year, thousands of young people arrive at specialist clinics with strange, unsettling experiences: whispering voices no one else can hear, a creeping suspicion that classmates are watching them, thoughts that seem to slip out of their control. They meet criteria for what psychiatrists call clinical high risk for psychosis, or CHR-P, a state in which attenuated psychotic symptoms have begun to surface but full-blown illness has not yet taken hold. What happens next has always been maddeningly unpredictable. Some of these individuals go on to develop schizophrenia or a related psychotic disorder, while others recover entirely and never look back. Now, one of the most comprehensive syntheses ever attempted has mapped out which factors separate the trajectories, and the answer is more encouraging, and more complex, than the field expected.

A team led by Cecilia Sanjuan-Ortiz of King’s College London, together with colleagues spanning Spain and the United Kingdom, conducted a systematic review following a pre-registered protocol and PRISMA reporting standards. Their search swept across five scientific databases to identify longitudinal studies that followed individuals at clinical high risk and reported which baseline characteristics were associated with remission from the high-risk state. After independent screening and data extraction by four reviewers, the team settled on fifty-one studies encompassing 10,073 participants from fifteen countries. The participants were young, averaging 19.1 years at study level with a range from 13.8 to 28.4 years, and just under half were female. Follow-up periods stretched from as short as eight months to as long as six years, giving researchers a meaningful window into how these young people fared over time.

The headline statistic is striking: roughly one-third of individuals at clinical high risk achieve remission from their CHR-P state at follow-up. That figure reframes the entire clinical conversation. For decades, research in this field has fixated on transition to psychosis, treating the onset of a diagnosable disorder as the outcome that matters most. But the new synthesis, published in the journal Schizophrenia, argues that remission deserves equal billing. A young person whose attenuated symptoms fade and who returns to their previous level of functioning has, in a very real sense, dodged the clinical bullet, and understanding what makes that outcome possible could transform early intervention from a blunt instrument into a precision tool.

Methodologically, the review carries considerable weight. The authors assessed risk of bias using a modified Newcastle-Ottawa Scale, and the results were reassuring: the mean score across studies was 7.7, with 92.1 percent of the included studies rated as high quality. Because the studies differed so substantially in their designs, measures and follow-up windows, the team could not pool results statistically; instead they performed a narrative synthesis, weighing how consistently each candidate predictor appeared across independent cohorts. That consistency, rather than any single effect size, became the currency of the review. A factor that showed up again and again in different countries, different clinics and different decades carries more evidentiary weight than one reported once, however dramatically.

What emerged was a clear hierarchy of predictors. The most robustly replicated factor was baseline functioning: ten separate studies found that individuals who were doing better in their daily lives, at school, at work and in relationships, when they first presented were more likely to remit. Close behind came symptom severity. Seven studies replicated the finding that lower levels of attenuated positive symptoms at baseline predicted remission, while three studies pointed to the same relationship for negative symptoms, the flattening of emotion, motivation and speech that often proves more disabling than hallucinations or delusions. Two studies independently identified lower self-disturbance, the unsettling sense that one’s thoughts, body or sense of self are slipping out of one’s own ownership, as a predictor of recovery.

Cognition emerged as another pillar. Four studies replicated the association between higher baseline verbal learning and later remission, and two studies each supported verbal memory, working memory and visual memory as predictors. The pattern makes intuitive sense: cognitive reserves buffer the impact of emerging symptoms and support the problem-solving, planning and social navigation that recovery demands. But the review did not stop at psychology. Three studies found that a preserved mismatch negativity amplitude, an electrophysiological brain response that fires when the brain detects an unexpected deviation in a repetitive sound stream, predicted remission. The mismatch negativity has long been studied as a candidate biomarker in psychosis research, and its appearance here, in the context of recovery rather than deterioration, suggests it may index the integrity of the very neural prediction machinery that psychosis disrupts.

Perhaps the most futuristic finding concerns language. Two studies replicated the association between speech fluency and connectedness and remission, joining a growing literature in which computational analysis of what patients say, how coherent their narratives are, how semantically rich their word choices, how smoothly their sentences flow, provides a window into underlying neurocognitive function. The idea that a short recorded speech sample could help clinicians stratify risk is no longer science fiction; it is an active frontier, and this review gives it a foothold in the CHR-P field specifically. Alongside these replicated findings, the authors flagged emerging but less consistent evidence for peripheral neurochemical, genetic and psychosocial or environmental factors, domains that remain underexplored and underpowered in the existing literature.

The review is candid about its limits. Substantial heterogeneity across the fifty-one studies, in how remission was defined, how predictors were measured and how long participants were followed, prevented any meta-analytic pooling and limits direct comparability of results. The authors also note that potentially protective factors associated with favourable outcomes remain understudied relative to risk factors, a bias that mirrors the field’s historical preoccupation with deterioration. Most studies examined predictors of remission from the high-risk state itself, but the relationships between remission, transition to psychosis and long-term functional recovery are not always straightforward, and the review stops short of claiming that any single marker can be used clinically today.

Still, the practical message is clear and, in its way, radical. Remission in CHR-P is consistently associated with lower symptom severity at baseline, preserved functioning and better cognitive performance, with self-disturbance, linguistic features and electrophysiological markers emerging as promising supplementary signals. No single domain, demographic, clinical, cognitive, neurophysiological or linguistic, tells the whole story. The authors argue that translation into clinical practice will require integrating information across domains rather than relying on single-domain indicators, effectively calling for multivariable prediction models that weigh a young person’s functioning, symptom profile, cognitive test results and possibly their speech patterns together. For clinicians running early intervention services, that means the most informative assessment may be the broadest one. For the young people and families sitting in those assessment rooms, the review offers something rarer than a risk calculator: evidence that for a substantial minority, and possibly with the right support, a much larger share, the story does not end in psychosis at all. It ends in recovery, and science is finally learning how to see it coming.

Subject of Research: Predictors of remission in individuals at clinical high risk for psychosis

Article Title: Predictors of remission in individuals at clinical high-risk for psychosis: a systematic review

Article References: Sanjuan-Ortiz, C., Laherran-Cantera, N., Aymerich, C., Dully, J., Ahmed, L., Salazar de Pablo, G., & Cella, M. (2026). Predictors of remission in individuals at clinical high-risk for psychosis: a systematic review. Schizophrenia. https://doi.org/10.1038/s41537-026-00809-z

Image Credits: AI Generated

DOI: 10.1038/s41537-026-00809-z

Keywords: clinical high risk for psychosis, CHR-P, remission, psychosis, systematic review, attenuated psychotic symptoms, cognition, verbal learning, mismatch negativity, self-disturbance, speech analysis, early intervention